A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

May 23, 2025 updated by: Bristol-Myers Squibb

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
701

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Caba, Argentina, 1426
        • Local Institution - 0138
      • Cordoba, Argentina, 5000
        • Local Institution - 0050
      • Cordoba, Argentina, X5004FHP
        • Local Institution - 0049
      • Tucuman, Argentina, 4000
        • Local Institution - 0047
    • Buenos Aires
      • Caba, Buenos Aires, Argentina, C1120AAT
        • Local Institution - 0046
      • Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, 1181
        • Local Institution - 0048
    • RIO Negro
      • Viedma, RIO Negro, Argentina, 8500
        • Local Institution - 0114
  • Australia
      • South Brisbane, Australia, 4101
        • Local Institution - 0129
    • New South Wales
      • North Ryde, New South Wales, Australia
        • Local Institution - 0002
      • Sydney, New South Wales, Australia, 2010
        • Local Institution - 0008
      • Sydney, New South Wales, Australia, 2139
        • Local Institution - 0009
      • Westmead, New South Wales, Australia, 2145
        • Local Institution - 0073
    • Queensland
      • Herston, Queensland, Australia, 4006
        • Local Institution - 0006
      • Southport, Queensland, Australia, 4215
        • Local Institution - 0001
    • South Australia
      • Elizabeth Vale, South Australia, Australia, 5112
        • Local Institution - 0004
    • Victoria
      • Malvern, Victoria, Australia, 3144
        • Local Institution - 0005
    • Western Australia
      • Doubleview, Western Australia, Australia, 6018
        • Local Institution - 0007
  • Brazil
      • Rio De Janeiro, Brazil, 20231-050
        • Local Institution - 0066
      • Sao Paulo, Brazil, 01323-020
        • Local Institution - 0074
      • Sao Paulo, Brazil, 05651901
        • Local Institution - 0061
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazil, 30130-090
        • Local Institution - 0057
    • RIO Grande DO SUL
      • Ijui, RIO Grande DO SUL, Brazil, 98700-000
        • Local Institution - 0119
      • Porto Alegre, RIO Grande DO SUL, Brazil, 90610-000
        • Local Institution - 0056
      • Porto Alegre, RIO Grande DO SUL, Brazil, 91350-200
        • Local Institution - 0060
    • Sao Paulo
      • Barretos, Sao Paulo, Brazil, 14784-400
        • Local Institution - 0058
  • Chile
    • Metropolitana
      • Santiago, Metropolitana, Chile, 8420383
        • Local Institution - 0045
  • Czechia
      • Hradec Kralove, Czechia, 500 05
        • Local Institution - 0034
      • Olomouc, Czechia, 779 00
        • Local Institution - 0033
  • Germany
      • Aachen, Germany, 52074
        • Local Institution - 0013
      • Bonn, Germany, 53127
        • Local Institution - 0016
      • Essen, Germany, 45136
        • Local Institution - 0117
      • Jena, Germany, 07747
        • Local Institution - 0023
      • Muenchen, Germany, 81675
        • Local Institution - 0010
      • Nuernberg, Germany, 90419
        • Local Institution - 0014
      • Tuebingen, Germany, 72076
        • Local Institution - 0011
  • Greece
      • Athens, Greece, 115 28
        • Local Institution - 0082
      • Thessaloniki, Greece, 546 45
        • Local Institution - 0083
  • Israel
      • Haifa, Israel, 3109601
        • Local Institution - 0072
      • Kfar Saba, Israel, 44281
        • Local Institution - 0070
      • Petah Tikva, Israel, 49414
        • Local Institution - 0071
      • Ramat Gan, Israel, 52621
        • Local Institution - 0069
  • Italy
      • Arezzo, Italy, 52100
        • Local Institution - 0054
      • Milano, Italy, 20132
        • Local Institution - 0052
      • Napoli, Italy, 80131
        • Local Institution - 0055
      • Padova, Italy, Padova
        • Local Institution - 0053
      • Pavia, Italy, 27100
        • Local Institution - 0051
      • Pavia, Italy, 27100
        • Local Institution - 0147
      • Terni, Italy, 05100
        • Local Institution - 0172
  • Japan
      • Chiba, Japan, 260-8717
        • Local Institution - 0167
      • Fukuoka, Japan, 812-8582
        • Local Institution - 0161
      • Nagasaki, Japan, 8528501
        • Local Institution - 0162
      • Tokyo, Japan, 160-8582
        • Local Institution - 0149
      • Yamagata, Japan, 9909585
        • Local Institution - 0165
    • Akita
      • Akita-shi, Akita, Japan, 010-8543
        • Local Institution - 0148
    • Aomori
      • Hirosaki, Aomori, Japan, 036-8563
        • Local Institution - 0156
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 0608543
        • Local Institution - 0164
      • Sapporo-shi, Hokkaido, Japan, 0608648
        • Local Institution - 0157
    • Hyogo
      • Kobe, Hyogo, Japan, 6500017
        • Local Institution - 0168
    • Iwate
      • Morioka, Iwate, Japan, 0208505
        • Local Institution - 0159
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 236-0004
        • Local Institution - 0171
      • Yokohama, Kanagawa, Japan, 241-8515
        • Local Institution - 0166
    • Niigata
      • Niigata-shi, Niigata, Japan, 9518520
        • Local Institution - 0150
    • Okayama
      • Okayama-shi, Okayama, Japan, 7008558
        • Local Institution - 0169
    • Osaka
      • Osaka-shi, Osaka, Japan, 5418567
        • Local Institution - 0170
      • Osakasayamashi, Osaka, Japan, 5898511
        • Local Institution - 0160
      • Suita-shi, Osaka, Japan, 565-0871
        • Local Institution - 0163
    • Osaka-shi
      • Osaka, Osaka-shi, Japan, 545-8586
        • Local Institution - 0154
    • Saitama
      • Hidaka-shi, Saitama, Japan, 3501298
        • Local Institution - 0155
    • Tokushima
      • Tokushima-shi, Tokushima, Japan, 7708503
        • Local Institution - 0153
    • Tokyo
      • Adachi-ku, Tokyo, Japan, 123-8558
        • Local Institution - 0152
      • Bunkyo-ku, Tokyo, Japan, 1138603
        • Local Institution - 0151
      • Bunkyo-ku, Tokyo, Japan, 1138519
        • Local Institution - 0158
      • Minato-ku, Tokyo, Japan, 105-8470
        • Local Institution - 0173
  • Mexico
    • Distrito Federal
      • Ciudad de Mexico, Distrito Federal, Mexico, 06100
        • Local Institution - 0062
      • Mexico, Distrito Federal, Mexico, 14080
        • Local Institution - 0116
      • Tlalpan, Distrito Federal, Mexico, 14080
        • Local Institution - 0115
    • Jalisco
      • Zapopan, Jalisco, Mexico, 45070
        • Local Institution - 0108
    • Nuevo LEON
      • Monterrey, Nuevo LEON, Mexico, 64060
        • Local Institution - 0143
    • Nuevo Leon
      • Monterrey, Nuevo Leon, Mexico, 64460
        • Local Institution - 0064
      • Monterrey, Nuevo Leon, Mexico, 64000
        • Local Institution - 0065
    • Querétaro
      • Santiago de Queretaro, Querétaro, Mexico, 76000
        • Local Institution - 0063
    • Yucatan
      • Merida, Yucatan, Mexico, 97125
        • Local Institution - 0136
  • Poland
      • Biala Podlaska, Poland, 21-500
        • Local Institution - 0084
      • Bydgoszcz, Poland, 85796
        • Local Institution - 0130
      • Gdansk, Poland, 80-219
        • Local Institution - 0085
  • Romania
      • Cluj-Napoca, Romania, 400015
        • Local Institution - 0021
      • Craiova, Romania, 200542
        • Local Institution - 0022
  • Russian Federation
      • Moscow, Russian Federation, 125284
        • Local Institution - 0020
      • Saint-Petersburg, Russian Federation, 197758
        • Local Institution - 0099
  • Spain
      • Barcelona, Spain, 08035
        • Local Institution - 0125
      • Madrid, Spain, 28009
        • Local Institution - 0121
      • Madrid, Spain, 28041
        • Local Institution - 0120
      • Santander, Spain, 39008
        • Local Institution - 0144
      • Sevilla, Spain, 41013
        • Local Institution - 0124
      • Valencia, Spain, 46014
        • Local Institution - 0123
  • Turkey
      • Ankara, Turkey, 06018
        • Local Institution - 0107
      • Ankara, Turkey, 06800
        • Local Institution - 0094
      • Ankara, Turkey, 06620
        • Local Institution - 0139
      • Antalya, Turkey, 07070
        • Local Institution - 0096
      • Denizli, Turkey, 20070
        • Local Institution - 0097
      • Edirne, Turkey, 22030
        • Local Institution - 0095
      • Istanbul, Turkey, 34300
        • Local Institution - 0146
  • United Kingdom
      • London, United Kingdom, EC1A 7BE
        • Local Institution - 0111
      • Manchester, United Kingdom, M20 4BX
        • Local Institution - 0109
      • Truro, United Kingdom, TR1 3LJ
        • Local Institution - 0140
  • United States
    • Alabama
      • Daphne, Alabama, United States, 36526
        • Local Institution - 0077
    • Arizona
      • Goodyear, Arizona, United States, 85338
        • Local Institution - 0044
      • Tucson, Arizona, United States, 85724-5024
        • Local Institution - 0132
    • California
      • Bakersfield, California, United States, 93309
        • Local Institution - 0133
      • Los Angeles, California, United States, 90404
        • Local Institution - 0093
      • Redondo Beach, California, United States, 90277
        • Local Institution - 0090
      • San Luis Obispo, California, United States, 93401
        • Local Institution - 0088
      • Santa Maria, California, United States, 93454
        • Central Coast Medical Oncology Corporation
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Local Institution - 0103
    • Georgia
      • Athens, Georgia, United States, 30607
        • Local Institution - 0127
      • Newnan, Georgia, United States, 30265
        • Local Institution - 0086
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Local Institution - 0036
      • Zion, Illinois, United States, 60099
        • Local Institution - 0042
    • Indiana
      • Fort Wayne, Indiana, United States, 46804
        • Local Institution - 0091
    • Kansas
      • Wichita, Kansas, United States, 67214
        • Local Institution - 0087
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Local Institution - 0113
      • Boston, Massachusetts, United States, 02215
        • Local Institution - 0037
    • Missouri
      • Kansas City, Missouri, United States, 64132
        • Local Institution - 0106
      • Saint Louis, Missouri, United States, 63110
        • Local Institution - 0035
    • Nevada
      • Las Vegas, Nevada, United States, 89169
        • Local Institution - 0102
    • New York
      • Buffalo, New York, United States, 14263
        • Local Institution - 0040
      • New York, New York, United States, 10065
        • Local Institution - 0017
    • Oregon
      • Portland, Oregon, United States, 97239
        • Local Institution - 0067
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • Local Institution - 0135
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Local Institution - 0105
    • Texas
      • Austin, Texas, United States, 78705
        • Local Institution - 0080
      • Dallas, Texas, United States, 75246
        • Local Institution - 0075
      • Houston, Texas, United States, 77030
        • Local Institution - 0068
      • Sherman, Texas, United States, 75090
        • Local Institution - 0078
    • Virginia
      • Norfolk, Virginia, United States, 23502
        • Local Institution - 0131

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Histological confirmation of RCC with a clear-cell component, including participants who may also have sarcomatoid features
  • Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC

  • No prior systemic therapy for RCC with the following exception:

    i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets VEGF or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy

Exclusion Criteria:

  • Any active CNS metastases
  • Any active, known or suspected autoimmune disease
  • Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization
  • Participants who have received a live/attenuated vaccine within 30 days of first treatment

Other protocol defined inclusion/exclusion criteria could apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Doublet
Nivolumab and Cabozantinib
Biological: Nivolumab
Specified dose on specified day
Other Names:
  • BMS-936558
  • Opdivo
Drug: Cabozantinib
Specified dose on specified days
Other Names:
  • Cabometyx
Active Comparator: Monotherapy
Sunitinib
Drug: Sunitinib
Specified dose on specified days.
Other Names:
  • Sutent
Experimental: Triplet

Nivolumab, Ipilimumab, Cabozantinib

*Enrollment to the triplet arm was discontinued by protocol amendment
Biological: Ipilimumab
Specified dose on specified days
Other Names:
  • BMS-734016
  • Yervoy

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Progression Free Survival (PFS)
Time Frame: From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)
PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive disease (PD); 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study
From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: From randomization date to death date (Up to 31 months)
Overall Survival is defined as the time between the date of randomization and the date of death due to any cause. For participants that are alive, their survival time will be censored at the date of last contact date (or "last known alive date").
From randomization date to death date (Up to 31 months)
Objective Response Rate (ORR)
Time Frame: Up to 31 Months

Objective Response Rate (ORR) is defined as the percentage of randomized participants who achieve a best response of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized participants.

Complete response (CR): Disappearance of all target lesions. Partial response (PR): 30% decrease in the sum of diameters of target lesions.
Up to 31 Months
Number of Participants Experiencing Adverse Events (AEs)
Time Frame: From first dose to 100 days following last dose (Up to 32 Months)
Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame.
From first dose to 100 days following last dose (Up to 32 Months)
Number of Participants Experiencing Serious Adverse Events (SAEs)
Time Frame: From first to dose to 100 days following last dose (Up to 32 months)
Number of participants experiencing various types of any grade serious adverse events (SAEs) during the specified time frame.
From first to dose to 100 days following last dose (Up to 32 months)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
Time Frame: From first dose to 30 days following last dose (Up to 30 months)
Number of participants experiencing various types of any grade adverse events (AEs) leading to discontinuation during the specified time frame.
From first dose to 30 days following last dose (Up to 30 months)
Number of Deaths
Time Frame: From first dose to (up to 31 months) following first dose
Number of deaths due to any cause during the specified time frame.
From first dose to (up to 31 months) following first dose
Number of Participants With Laboratory Abnormalities
Time Frame: From first dose to 30 days following last dose (Up to 30 Months)
Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame.
From first dose to 30 days following last dose (Up to 30 Months)
Number of Participants With Laboratory Values Grade Shifting From Baseline
Time Frame: From first dose to 30 days following last dose (Up to 30 Months)
Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame.
From first dose to 30 days following last dose (Up to 30 Months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Ono Pharmaceutical Co. Ltd
Exelixis

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 23, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 12, 2020

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 16, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 3, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 3, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 4, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 6, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 23, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CA209-9ER
  • 2017-000759-20 (EudraCT Number)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Cell Carcinoma

Clinical Trials on Ipilimumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings